Answers are grounded in this paper and cite their sources.
Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) have demonstrated efficacy in improving mortality and cardiovascular (CV) outcomes. However, the impact of GLP-1RAs therapy on cardiorenal outcomes of diabetic patients at the commencement of dialysis remains unexplored.
No takes yet. Share an insight, caveat, or question.
Lai et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: